File(s) not publicly available

Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds

posted on 2023-04-04, 12:56 authored by Anna MånbergAnna Månberg


Increased knowledge of the evolution of molecular changes in neurodegenerative disorders such as Alzheimer’s disease (AD) is important for the understanding of disease pathophysiology and also crucial to be able to identify and validate disease biomarkers. While several biological changes that occur early in the disease development have already been recognised, the need for further characterization of the pathophysiological mechanisms behind AD still remains.

In this study, we investigated cerebrospinal fluid (CSF) levels of 104 proteins in 307 asymptomatic 70-year-olds from the H70 Gothenburg Birth Cohort Studies using a multiplexed antibody-based technology.

The protein levels were first correlated with the core AD CSF biomarker concentrations of total tau, phospho-tau and Aβ42 in all individuals. Sixty-three proteins showed significant correlations with either total tau, phospho-tau or Aβ42. Thereafter, individuals were divided based on CSF Aβ42/Aβ40 ratio and Clinical Dementia Rating (CDR) score to determine if early changes in pathology and cognition had an effect on the correlations. We compared the associations of the analysed proteins to CSF markers between groups and found 33 proteins displaying significantly different associations for amyloid-positive individuals and amyloid negative individuals, as defined by the CSF Aβ42/Aβ40 ratio. No differences in the associations could be seen for individuals divided by CDR score.

We identified a series of transmembrane proteins, proteins associated to or anchored to the plasma membrane, and proteins involved in or connected to synaptic vesicle transport that were associated with CSF biomarkers of amyloid and tau pathology in AD. Further studies are needed to explore their role in AD pathophysiology.

Data Access Statement

The dataset contains relative protein levels as well as CSF concentrations of amyloid beta and tau which constitutes sensitive personal information that fall under GDPR. Therefore, access to data and related code is restricted. The data can be made available upon reasonable request, in accordance with GDPR and other regulations regarding data sharing.

A reasonable request should contain:
1) Name of PI and host organisation
2) Contact details
3) Scientific purpose of data access request
4) Commitment to inform when the data has been used in a publication
5) Commitment not to host or share the data outside the requesting organisation
6) Statement of non-commercial use of data



KTH Royal Institute of Technology

Access request email